Share Price:

APNASPENAspen Pharmacare Hldgs11750520 (4.63%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Opening of European Commission proceedings

Aspen confirms that the European Commission has opened proceedings to investigate certain actions of Aspen Holdings and certain of its European subsidiaries.

While Aspen is not currently in a position to comment on these proceedings, it reaffirms its commitment to fair and open competition in markets in the European Union and around the world. Aspen takes compliance with competition laws very seriously and will work constructively with the European Commission in its process.

Shareholders are advised that any material developments in these proceedings will be communicated through SENS. Shareholders should exercise care when reacting to information on this matter which has not been released by Aspen Holdings.

Facebook
Twitter
LinkedIn
Pinterest

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: